Genmab A/S (NASDAQ:GMAB - Get Free Report) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 2,340,000 shares, an increase of 23.2% from the October 15th total of 1,900,000 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 874,600 shares, the short-interest ratio is currently 2.7 days.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of GMAB. SG Americas Securities LLC raised its position in Genmab A/S by 360.5% during the first quarter. SG Americas Securities LLC now owns 29,500 shares of the company's stock valued at $882,000 after purchasing an additional 23,094 shares in the last quarter. Capital International Investors raised its holdings in shares of Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company's stock valued at $130,805,000 after buying an additional 315,355 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in Genmab A/S by 26.3% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company's stock worth $5,480,000 after buying an additional 45,376 shares during the last quarter. Choreo LLC bought a new position in Genmab A/S during the second quarter valued at approximately $776,000. Finally, Renaissance Technologies LLC raised its stake in shares of Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after acquiring an additional 103,859 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.
Ad Stansberry Research
"This Could Be Worse Than the Great Depression, the Dot-Com Crash, and the 2008 Crisis Combined"
What Are These Billionaire Investors Afraid Of?
Billionaires Warren Buffett, Stanley Druckenmiller, George Soros, and David Tepper have all sold off massive U.S. stock positions, including shares of Nvidia, Apple, and Bank of America. Billionaire Ray Dalio, who runs one of the world’s most successful hedge funds, says, “Things are going to get worse for our economy.” What are these billionaires so worried about?
Click here to see why experts and insiders may be preparing for the biggest financial crisis of the
Genmab A/S Trading Down 2.8 %
Shares of GMAB stock traded down $0.59 during trading hours on Friday, reaching $20.59. The stock had a trading volume of 1,310,575 shares, compared to its average volume of 1,554,565. The stock's fifty day simple moving average is $23.81 and its 200 day simple moving average is $26.16. The firm has a market capitalization of $13.63 billion, a PE ratio of 19.99, a PEG ratio of 0.64 and a beta of 0.99. Genmab A/S has a 12 month low of $20.50 and a 12 month high of $32.89.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The business had revenue of $816.10 million for the quarter, compared to analysts' expectations of $838.20 million. During the same quarter in the previous year, the firm earned $0.47 earnings per share. As a group, equities research analysts anticipate that Genmab A/S will post 1.28 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on GMAB. Redburn Atlantic initiated coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a "buy" rating for the company. HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Wednesday, October 16th. Truist Financial dropped their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating on the stock in a report on Monday, September 9th. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Finally, BMO Capital Markets reissued an "outperform" rating and issued a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $45.20.
Check Out Our Latest Analysis on GMAB
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
